Balyasny Asset Management LLC Glycomimetics Inc Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$2.55 - $3.49 $103,420 - $141,543
40,557 New
40,557 $121,000
Q2 2018

Aug 14, 2018
SELL
$14.63 - $19.19 $1.49 Million - $1.96 Million
-101,986 Closed
0 $0
Q1 2018

May 15, 2018
BUY
$16.06 - $25.35 $1.64 Million - $2.59 Million
101,986 New
101,986 $1.66 Million

Others Institutions Holding GLYC

# of Institutions
35
Shares Held
17.8M
Call Options Held
0
Put Options Held
0
View Full List

About GLYCOMIMETICS INC

GLYC Quotes by TradingView
  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $16.3M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email